Esperion Therapeutics (NASDAQ:ESPR – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts ...

Esperion Therapeutics (NASDAQ: ESPR) today announced it has entered into a license and distribution agreement with CSL Seqirus (ASX:CSL) for the exclusive rights to commercialize NEXLETOL ® (bempedoic ...

Therapeutics announced it has entered into a license and distribution agreement with CSL Seqirus for the exclusive rights to ...

Total Revenue Grew 186% Y/Y to $332.3 Million; FY24 U.S. Net Product Revenue Grew 48% Y/Y to $115.7 Million – –Q4 Total Revenue Grew 114% Y/Y to $69.1 Million; Q4 U.S. Net Product Revenue Grew 52% Y/Y ...

Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) is expected to issue its quarterly earnings data before the market opens on Tuesday, March 4th. Analysts expect the company to announce earnings ...

ESPERION THERAPEUTICS ($ESPR) posted quarterly earnings results on Tuesday, March 4th. The company reported earnings of -$0.10 per share, beating estimates of -$0.15 ...

I would now like to turn the call over to Alina Venezia, Director of Investor Relations for Esperion Therapeutics. You may begin. Thank you, operator. Good morning and welcome to Esperion's fourth ...

ANN ARBOR, Mich., March 03, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics (NASDAQ: ESPR) today announced it has entered into a license and distribution agreement with CSL Seqirus (ASX:CSL ...

March 04, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update.